BioSpace News Archive

Fiscal 2021 Third Quarter Highlights Net sales of $71.2 million increased 2.0% compared to the prior-year quarter Gross margin of 54.1%, a decline of 370 basis points year over year GAAP loss per share of $0.09 and adjusted earnings per share of $0.02

According to the report, the global collagen peptide and gelatin market was valued at US$ 5,976.9 Mn in 2018 and is projected to expand at a CAGR of 8.7% from 2019 to 2027

ePharmacy refers to an intermediate between seller and consumer for the purpose of selling of medicine. It is an online platform for the sale of medicines and is also widely known as mail order pharmacy and internet pharmacy.

According to the report, the global menopausal hot flashes market was valued at approximately US$ 9.5 Bn in 2018. It is expected to expand at a CAGR of 6% during the forecast period from 2019 to 2027.

According to the report, the global peptide therapeutics market was valued at US$ 25.0 Bn in 2018 and is anticipated to expand at a CAGR of 7.9% from 2019 to 2027

Heightened mortality rates due to improper diagnosis is accelerating R&D efforts to promote advanced diagnostics

Burgeoning cases of urinary and bladder cancer is spurring researchers to verify and reintroduce new innovations for the ostomy care treatment

Genuity Science, a genomics and data-sourcing, analytics and insights organization, announced that Tom Chittenden, PhD, DPhil, PStat, Chief Data Science Officer and Founding Director of the Genuity Science Advanced Artificial Intelligence Research Laboratory, is a winner of the Artificial Intelligence Excellence Awards presented by the Business Intelligence Group.

Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for vadadustat, Akebia’s investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for the treatment of anemia due to chronic kidney disease in both adult patients on dialysis and adult patients not on dialysis.

Clinical and pathological findings from clinical trial of the Bria-IMT™ regimen alone and in combination with immune checkpoint inhibitors in advanced breast cancer will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2021, April 10-15 and May 17-21.